Trial of Eribulin in Patients Who Do Not Achieve Pathologic Complete Response (pCR) Following Neoadjuvant Chemotherapy
Status:
Completed
Trial end date:
2017-04-03
Target enrollment:
Participant gender:
Summary
The investigators propose to evaluate eribulin as adjuvant therapy in breast cancer patients
who have residual invasive disease in breast or lymph node tissue following standard
neoadjuvant chemotherapy and surgery regimen. Three cohorts of patients will be evaluated
separately based on tumor type: triple-negative, hormone-receptor-positive/HER2-negative, and
HER2-positive breast cancers.